August 27, 2021
Search
37 Result(s)
November 17, 2019
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
November 06, 2021
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
July 06, 2021
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
June 28, 2021
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
November 18, 2020
New: Empagliflozin reduced risk of recurrent CV events
July 30, 2020
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
July 25, 2023
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
September 09, 2021
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
May 26, 2020
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction
November 03, 2023
Boehringer Ingelheim achieves major milestone in chronic kidney disease
December 11, 2023
EU approves Jardiance® for treatment of type 2 diabetes in children aged 10 years and above
December 13, 2019
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
June 06, 2022
Jardiance® (empagliflozin) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
May 21, 2021
Positive CHMP opinion for a heart failure indication
June 21, 2021
Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction
March 16, 2022
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
January 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
March 12, 2020
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease
March 20, 2020
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Diabetes
Empagliflozin in real-world clinical care
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
December 07, 2022